Suicide Risk in a National VA Sample: Roles of Psychiatric Diagnosis, Behavior Regulation, Substance Use, and Smoking

Click here to read the JCP CME article

Overview

Predicting suicide is difficult, as suicidal behavior is not linked solely to any single behavior or psychiatric diagnosis. This study compared risk of suicidal behavior among a transdiagnostic sample of Veterans with varying disorders and behaviors. 

Read the whole article at psychiatrist.com here: 
Suicide Risk in a National VA Sample: Roles of Psychiatric Diagnosis, Behavior Regulation, Substance Use, and Smoking 

© Copyright 2022 Physicians Postgraduate Press, Inc.

Target Audience

Psychiatrists

Learning Objectives

Screen patients for risk factors for suicide (eg, tobacco smoking and impulsivity) that transcend individual psychiatric disorders 

Activity summary
Available credit: 
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Participation
Activity opens: 
06/06/2022
Activity expires: 
07/01/2023
Cost:
$0.00

CME Background

Articles are selected for credit designation based on an assessment of the educational needs of CME participants, with the purpose of providing readers with a curriculum of CME articles on a variety of topics throughout each volume. Activities are planned using a process that links identified needs with desired results.

CME Objective

After studying this article, you should be able to:

  • Screen patients for risk factors for suicide (eg, tobacco smoking and impulsivity) that transcend individual psychiatric disorders

Statement of Need and Purpose

Identifying patients at risk for suicide remains an important yet elusive task for clinicians. Given the lack of a one-to-one relationship between suicide risk and any specific mental disorder, clinicians need education on screening patients for risk factors (eg, tobacco smoking and impulsivity) that transcend individual psychiatric disorders and that may be shared by multiple conditions.

Release, Expiration, and Review Dates

This educational activity was published in June 2022 and is eligible for AMA PRA Category 1 Credit™ through June, 30 2023. The latest review of this material was May 2022.

Disclosure of Off-Label Usage

Dr Swann has determined that, to the best of his knowledge, lithium, divalproex, carbamazepine, ketamine, and clozapine are not approved by the US Food and Drug Administration for the treatment of suicide prevention, aggression, or impulsivity.

Funding/Support

Dr Swann received support from the Linda and John Griffin Endowment, Houston, Texas.

Role of the Sponsor

The Linda and John Griffin Endowment had no role in the conduct of the study or publication of the results.

Previous presentation

Data from this article were presented (as virtual presentations) at the 2021 Meetings of the Society for Biological Psychiatry (April 28–May 1, 2021) and the International Association for Suicide Research-American Foundation for Suicide Research (October 26, 2021).

Acknowledgments

The authors thank the Michael E. DeBakey Veterans Affairs Medical Center, Houston, Texas, for facilities and support for this research and the Million Veterans Program, CSRD, for access to relevant data.

Faculty Affiliation

Alan C. Swann, MD
Michael E. DeBakey Veterans Affairs Medical Center, Houston, Texas
Department of Psychiatry and Behavioral Sciences, Baylor College of Medicine, Houston, Texas

David P. Graham, MD
Michael E. DeBakey Veterans Affairs Medical Center, Houston, Texas
Department of Psychiatry and Behavioral Sciences, Baylor College of Medicine, Houston, Texas

Anna V. Wilkinson, PhD
University of Texas Health School of Public Health in Austin and Michael & Susan Dell Center for Healthy Living, Austin, Texas

Thomas R. Kosten, MD
Michael E. DeBakey Veterans Affairs Medical Center, Houston, Texas
Department of Psychiatry and Behavioral Sciences, Baylor College of Medicine, Houston, Texas

*Corresponding author: Alan C. Swann, MD, 1977 Butler Blvd, Ste E4.400, Houston, TX 77030 ([email protected]).

Financial Disclosure 

All individuals in a position to influence the content of this activity were asked to complete a statement regarding all relevant personal financial relationships between themselves or their spouse/partner and any commercial interest. The CME Institute has resolved any conflicts of interest that were identified. In the past 3 years, Marlene P. Freeman, MD, Editor in Chief, has received research funding from JayMac and Sage; has been a member of the Independent Data Safety and Monitoring Committee for Janssen (Johnson & Johnson), Novartis, and Neurocrine; and has served on advisory boards for Eliem and Sage. As an employee of Massachusetts General Hospital (MGH), Dr Freeman works with the MGH National Pregnancy Registry, which receives funding from Alkermes, Aurobindo, AuroMedics, Johnson & Johnson/Janssen, Otsuka, Sage, Sunovion, Supernus, and Teva, and works with the MGH Clinical Trials Network and Institute, which receives research funding from multiple pharmaceutical companies and the National Institute of Mental Health. Dr Freeman has also received royalties through MGH for the Massachusetts General Hospital Female Reproductive Lifecycle and Hormones Questionnaire. No member of the CME Institute staff reported any relevant personal financial relationships. The authors have no potential conflicts of interest relative to this work.

Accreditation Statement

The CME Institute of Physicians Postgraduate Press, Inc., is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation

The CME Institute of Physicians Postgraduate Press, Inc., designates this journal-based CME activity for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Note: The American Nurses Credentialing Center (ANCC) and the American Academy of Physician Assistants (AAPA) accept certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by the ACCME.

Available Credit

  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Participation

Price

Cost:
$0.00
Please login or register to take this activity.

Register for free on our site to participate in this and many free CME courses. 

Available credit: 

  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Participation

Learning Objective 

Screen patients for risk factors for suicide (eg, tobacco smoking and impulsivity) that transcend individual psychiatric disorders 

Target Audience

Psychiatrists

Read the whole article at psychiatrist.com here: 
Suicide Risk in a National VA Sample: Roles of Psychiatric Diagnosis, Behavior Regulation, Substance Use, and Smoking